EUVIMEDEUVIMED entdecken
Crossref

LAMP2-Centered Autophagy Network and HDAC Inhibitors as Therapeutic Leads in Alzheimer’s and Parkinson’s Diseases: A Bioinformatic Analysis

İdil Selen Sangün, Bilge Sezin Akkoç, Melis Sert, Ebrar Azak, Gizem Ayna Duran

International Journal of Advances in Engineering and Pure Sciences · 20.03.2026 · 38 (1) · 118-137

DOI: 10.7240/jeps.1758216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Advances in Engineering and Pure Sciences, online erschienen am 20.03.2026. Verfasst von İdil Selen Sangün und 4 weiteren Autor:innen. Die Arbeit nennt 102 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most commonly diagnosed, and both present with distinct proteinopathies and progressive neuronal loss. Studies have implicated autophagy dysfunction as a common mechanism in both diseases. Therefore, the primary objective of our study is to use bioinformatics techniques to identify commonly upregulated genes associated with autophagy and apoptosis in AD and PD and to develop novel therapeutic agents targeting these genes. Using publicly available transcriptomic data (GSE5281 and GSE48350 for AD; GSE49036 for PD), differentially expressed genes (DEGs) are identified and restricted to autophagy and apoptosis related genes compiled from the Human Autophagy Database. According to our results, the genes CARD8, FXN, LAMP2, EVI2B, MYOT, P2RX7, and MEGF10 are consistently upregulated in both conditions, while ELAPOR1 is downregulated. Our PPI network analysis results highlight LAMP2 as a central molecule regulating lysosomal-autophagic fusion. Gene enrichment analyses implicate pathways involved in autophagy, lysosomal activity, and inflammation. Drug repurposing analysis using the DSigDB database on the Enrichr platform has shown that the histone deacetylase (HDAC) inhibitors Vorinostat (suberoylanilide hydroxamic acid, SAHA), Trichostatin A (TSA), and Valproic Acid (VPA) stand out as promising agents that may regulate this common gene network. These findings provide a number of autophagy- and apoptosis-related targets and therapies with the potential to address shared pathological features of AD and PD.

Zitieren

APA

Sangün, İ. S., Akkoç, B. S., Sert, M., Azak, E., & Duran, G. A. (2026). LAMP2-Centered Autophagy Network and HDAC Inhibitors as Therapeutic Leads in Alzheimer’s and Parkinson’s Diseases: A Bioinformatic Analysis. International Journal of Advances in Engineering and Pure Sciences, 38(1), 118-137. https://doi.org/10.7240/jeps.1758216

Vancouver

Sangün İS, Akkoç BS, Sert M, Azak E, Duran GA. LAMP2-Centered Autophagy Network and HDAC Inhibitors as Therapeutic Leads in Alzheimer’s and Parkinson’s Diseases: A Bioinformatic Analysis. International Journal of Advances in Engineering and Pure Sciences. 2026;38(1):118-137. doi:10.7240/jeps.1758216

BibTeX
@article{Sangn2026,
  author = {Sangün, İdil Selen and Akkoç, Bilge Sezin and Sert, Melis and Azak, Ebrar and Duran, Gizem Ayna},
  title = {LAMP2-Centered Autophagy Network and HDAC Inhibitors as Therapeutic Leads in Alzheimer’s and Parkinson’s Diseases: A Bioinformatic Analysis},
  journal = {International Journal of Advances in Engineering and Pure Sciences},
  year = {2026},
  volume = {38},
  number = {1},
  pages = {118--137},
  doi = {10.7240/jeps.1758216}
}
Kostenlos starten →